JoomlaWatch Stats 1.2.7 by Matej Koval

Can A et al. publications with regards to research on human umbilical cord (hUC) and

hUC-derived mesenchymal stem cells.


  1. Seyihoglu B, Orhan I, Okudur N, Aygun HK, Bhupal M, Yavuz Y, Can A. 20 Years of treating ischemic cardiomyopathy with mesenchymal stromal cells: a meta-analysis and systemic review. Cytotherapy 26(12):  1443-1457, 2024.    https://doi.org/10.1016/j.jcyt.2024.07.004
  2. Ulus T, Mungan C, Kurtoglu M, Celikkan FT, Akyol M, Sucu M, Toru M, Gul SS, Cinar O, Can A. Intramyocardial transplantation of umbilical cord mesenchymal stromal cells in chronic ischemic cardiomyopathy: A controlled, randomized clinical trial (HUC-HEART Trial). International Journal of Stem Cells 13: 364-376, 2020.
  3. Can A, Coskun H. The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect. Stem Cells Translational Medicine. 25: 2886-2895, 2020.
  4. Yigman Z. Ozdemir ED, Turan NN, Ulus AT, Can A. Umbilical cord mesenchymal stromal cells engraft and transdifferentiate into cardiomyocyte-like cells following acute myocardial ischemia. Acta Histochemica 122: 151578, 2020.
  5. Celikkan FT, Mungan C, Sucu M, Ulus AT, Cinar O, Ili EG, Can A. Optimizing the transport and storage of current Good Manufacturing Practice-grade human umbilical cord mesenchymal stromal cells for transplantation. Cytotherapy. 21: 64-75, 2019.
  6. Can A, Celikkan FT, Cinar O. Umbilical cord mesenchymal stromal cell transplantations: A systemic analysis of clinical trials.Cytotherapy 19: 1351-1382; 2017.
  7. Can A, Ulus AT, Cinar O, Celikkan FT, Simsek E, Akyol M, Canpolat U, Erturk M, Kara F, Ilhan O. Human umbilical cord mesenchymal stromal cell transplantation in myocardial ischemia (HUC-HEART Trial). A study protocol of a phase 1/2 controlled and randomized trial in combination with coronary artery bypass grafting. Stem Cell Reviews and Reports 11: 752-760, 2015.
  8. Coskun H, Can A. The assessment of the in vivo to in vitro cellular transition of human umbilical cord multipotent stromal cells. Placenta 36: 232-239, 2015.
  9. Balci D, Can A. The assessment of cryopreservation conditions for human umbilical cord stroma-derived mesenchymal stem cells towards a potential use for stem cell banking. Current Stem Cell Research & Therapy 8: 60–72, 2013.
  10. Can A, Balci B. Isolation, culture, and characterization of human umbilical cord stroma-derived mesenchymal stem cells. Methods in Molecular Biology 698: 51–62, 2011.
  11. Oktar PA, Yildirim S, Balci D, Can A. Continual expression throughout the cell cycle and downregulation upon adipogenic differentiation makes nucleostemin a vital human MSC proliferation marker. Stem Cell Reviews and Reports 7: 413–424, 2011.
  12. Kocaefe C, Balcı D, Balcı Hayta B, Can A. Reprogramming of human umbilical cord stromal mesenchymal stem cells for myogenic differentiation and muscle repair. Stem Cell Reviews and Reports 6: 512–522, 2010.
  13. Karahuseyinoglu S, Kocaefe C, Balci D, Erdemli E, Can A. Functional structure of adipocytes differentiated from human umbilical cord stroma-derived stem cells. Stem Cells 28: 682–691, 2008.
  14. Can A, Karahuseyinoglu S. Concise Review: Human umbilical cord stroma with regard to the source of fetus-derived stem cells. Stem Cells 25: 2886–2895, 2007.
  15. Karahuseyinoglu S, Cinar O, Kilic E, Kara F, Akay GG, Demiralp DÖ, Tukun A, Uckan D, Can A. Biology of the stem cells in human umbilical cord stroma: In situ and in vitro surveys. Stem Cells 25: 319–331, 2007.